Trial Profile
Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs IPL-344 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunity Pharma
- 17 Jan 2024 According to an Immunity Pharma media release, results from this trial will be soon be submitted for publication in a scientific journal.
- 17 Jan 2024 Results presented in an Immunity Pharma Media Release.
- 03 Dec 2023 Planned End Date changed from 15 Aug 2022 to 1 Feb 2025.